125 related articles for article (PubMed ID: 19366069)
41. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
42. Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: a study of Japanese cases.
Maeda D; Ota S; Takazawa Y; Ohashi K; Mori M; Imamura T; Nakagawa S; Yano T; Taketani Y; Fukayama M
Virchows Arch; 2010 Nov; 457(5):597-608. PubMed ID: 20872013
[TBL] [Abstract][Full Text] [Related]
43. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
45. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
46. [Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma].
Wan T; Liu JH; Zheng LM; Cai MY; Ding T
Ai Zheng; 2009 Mar; 28(3):323-7. PubMed ID: 19619451
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
[TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
[TBL] [Abstract][Full Text] [Related]
49. An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in low-grade and high-grade ovarian serous carcinomas.
Mishra SK; Crasta JA
Int J Gynecol Cancer; 2010 May; 20(4):537-41. PubMed ID: 20442586
[TBL] [Abstract][Full Text] [Related]
50. Aggressive ovarian psammocarcinoma: a case report.
Zakkouri FA; Berrada N; Kettani F; Mrabti H; Jalil A; Errihani H
Eur J Gynaecol Oncol; 2011; 32(2):214-5. PubMed ID: 21614920
[TBL] [Abstract][Full Text] [Related]
51. Endometriosis-associated serous borderline tumor and endometrial stromal sarcoma of the ovary: a report of a rare lesion in an infant.
Ho RS; Chan GC; Ha SY; Ip PP
Int J Gynecol Pathol; 2012 Jan; 31(1):98-102. PubMed ID: 22123729
[TBL] [Abstract][Full Text] [Related]
52. Mesonephric-like Differentiation of Ovarian Endometrioid and High-grade Serous Carcinomas: Clinicopathological and Molecular Characteristics Distinct from Those of Mesonephric-like Adenocarcinoma.
Choi KH; Kim H; Bae GE; Lee SH; Woo HY; Kim HS
Anticancer Res; 2021 Sep; 41(9):4587-4601. PubMed ID: 34475087
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
[TBL] [Abstract][Full Text] [Related]
54. KRAS-mutated Uterine Endometrioid Carcinoma With Extensive Surface Changes Resulting in Striking Morphologic Mimicry of an Ovarian Serous Borderline Tumor.
Kir G; Olgun ZC; Gunel H; Ozen F; McCluggage WG
Int J Gynecol Pathol; 2020 Nov; 39(6):573-577. PubMed ID: 31855953
[TBL] [Abstract][Full Text] [Related]
55. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
56. Ovarian serous carcinoma: relationship of p53 and bcl-2 with tumor angiogenesis and VEGF expression.
Crasta JA; Mishra S; Vallikad E
Int J Gynecol Pathol; 2011 Nov; 30(6):521-6. PubMed ID: 21979585
[TBL] [Abstract][Full Text] [Related]
57. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
58. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
59. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
60. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
